VJHemOnc is committed to improving our service to you

ICML 2019 | Single agent ibrutinib produces long-term disease control in Waldenström’s: the pivotal trial

VJHemOnc is committed to improving our service to you

Steven Treon

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, presents the final report of the pivotal trial of ibrutinib monotherapy for previously treated Waldenström’s macroglobulinemia (NCT01614821). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter